Nuvig Therapeutics Secures $161M for Phase 2 Autoimmune Therapy Development

Nuvig Therapeutics has successfully attracted $161 million in Series B funding, a substantial increase from its previous Series A round of $47 million, indicating strong investor confidence in its innovative autoimmune therapies[1][2]. The funding involves significant contributions from major players like Sanofi Ventures, Bayer, Novo Holdings, and Bristol Myers Squibb, among others, and will support the advancement of Nuvig’s lead candidate, NVG-2089, into phase 2 clinical trials[1][3]. This novel Fc fragment immunomodulator is designed to target Type II Fc receptors, potentially providing a safer alternative to existing autoimmune disease treatments by maintaining immune balance instead of broadly suppressing immune function[2][3].